Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
US-2024158357-A1 · May 16, 2024 · US
2-aryl-4-quinazolinones and their pharmaceutical compositions
US9006239B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9006239-B2 |
| Application number | US-201313953847-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 30, 2013 |
| Priority date | Oct 20, 2011 |
| Publication date | Apr 14, 2015 |
| Grant date | Apr 14, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a compound of the formula I or a pharmaceutically acceptable salt, solvate or stereoisomer thereof: wherein Ar represents R 5 , R 7 , R 8 , R 2 ′, R 4 ′, R 5 ′, R 6 ′, R 7 ′, R 8 ′ independently represent H, OH, F, Cl, Br, methoxyl group, NH 2 group or NMe 2 group; X represents NH, O or S; and R 6 is selected from the group consisting of: pyrrolidinyl group, piperidinyl group, morpholino group, methoxyl group, and dimethylamine group. The present invention also provides a composition comprising the compound of formula I. The compound and the composition in accordance with the present invention are effective on treating or alleviating a disease or disorder, such as malignant glioma.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of the formula I or a pharmaceutically acceptable salt, solvate or stereoisomer thereof: wherein R 5 , R 7 and R 8 independently represent H, OH, F, Cl, Br, methoxyl group or NMe 2 group; Ar represents R 2 ′, R 4 ′, R 5 ′…
Assignees
Inventors
Classifications
- C07D239/91Primary
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9006239B2 cover?
- Provided is a compound of the formula I or a pharmaceutically acceptable salt, solvate or stereoisomer thereof: wherein Ar represents …
- Who is the assignee on this patent?
- Univ China Medical
- What technology area does this patent fall under?
- Primary CPC classification C07D239/91. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).